Sapience Therapeutics, SVP Research & Translational Sciences Jim Rotolo, FreeMind Elite, 19th NDFS скачать в хорошем качестве

Sapience Therapeutics, SVP Research & Translational Sciences Jim Rotolo, FreeMind Elite, 19th NDFS

Jim Rotolo is the Senior Vice President of Research and Translational Sciences at Sapience Therapeutics. Dr. Rotolo leads the Company’s discovery, pre-clinical and non-clinical development efforts, including the discovery and development of Sapience’s two lead SPEARS programs, ST101 and ST316. Prior to Sapience, Dr. Rotolo was Director of Pharmacology at ContraFect Corporation with roles in R&D, non-clinical development and clinical operations. He was responsible for directing in vivo studies supporting the progression of the company’s lead candidate from proof of concept into Phase 2 of clinical development, including PK/PD assessments to inform dose selection for Phase 1 and 2 studies. At Memorial Sloan-Kettering Cancer Center, Dr. Rotolo invented an engineered antibody-fragment-based therapeutic for medical radiation countermeasures and autoimmune indications. This antibody has been licensed for commercial development and is supported by the NIH Radiation Nuclear Countermeasures Program. Dr. Rotolo holds a B.S. in Chemistry from Emory University, an M.S. in Pharmacology and Toxicology from Long Island University, and a Ph.D. in Pharmacology and Immunology from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center. His work has resulted in over 20 publications and multiple patents/patent applications.